Emerson C Perin1, Ricardo Sanz-Ruiz2, Pedro L Sánchez2, José Lasso3, Rosa Pérez-Cano3, Juan C Alonso-Farto4, Esther Pérez-David2, Maria Eugenia Fernández-Santos5, Patrick W Serruys6, Henrick J Duckers6, Jens Kastrup7, Steven Chamuleau8, Yi Zheng1, Guilherme V Silva1, James T Willerson1, Francisco Fernández-Avilés9. 1. Stem Cell Center, Texas Heart Institute, Houston, TX. 2. Cardiology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain. 3. Plastic Surgery Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain. 4. Nuclear Medicine Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain. 5. Cell Production Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain. 6. Department of Interventional Cardiology, Thoraxcenter, Rotterdam, Utrecht, The Netherlands. 7. Cardiology Department, Rigshospitalet University Hospital, Copenhagen, Denmark. 8. Cardiology Department, University of Utrecht Medical Center, Utrecht, The Netherlands. 9. Cardiology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain. Electronic address: faviles@secardiologia.es.
Abstract
AIMS: Adipose-derived regenerative cells (ADRCs) can be isolated from liposuction aspirates and prepared as fresh cells for immediate administration in cell therapy. We performed the first randomized, placebo-controlled, double-blind trial to examine the safety and feasibility of the transendocardial injections of ADRCs in no-option patients with ischemic cardiomyopathy. METHODS AND RESULTS: Procedural, postoperative, and follow-up safety end points were monitored up to 36 months. After baseline measurements, efficacy was assessed by echocardiography and single-photon emission computed tomography (6, 12, and 18 months), metabolic equivalents and maximal oxygen consumption (MVO2) (6 and 18 months), and cardiac magnetic resonance imaging (6 months). We enrolled 21 ADRC-treated and 6 control patients. Liposuction was well tolerated, ADRCs were successfully prepared, and transendocardial injections were feasible in all patients. No malignant arrhythmias were seen. Adverse events were similar between groups. Metabolic equivalents and MVO2 values were preserved over time in ADRC-treated patients but declined significantly in the control group. The difference in the change in MVO2 from baseline to 6 and 18 months was significantly better in ADRC-treated patients compared with controls. The ADRC-treated patients showed significant improvements in total left ventricular mass by magnetic resonance imaging and wall motion score index. Single-photon emission computed tomography results suggested a reduction in inducible ischemia in ADRC-treated patients up to 18 months. CONCLUSION:Isolation and transendocardial injection of autologous ADRCs in no-option patients were safe and feasible. Our results suggest that ADRCs may preserve ventricular function, myocardial perfusion, and exercise capacity in these patients.
RCT Entities:
AIMS: Adipose-derived regenerative cells (ADRCs) can be isolated from liposuction aspirates and prepared as fresh cells for immediate administration in cell therapy. We performed the first randomized, placebo-controlled, double-blind trial to examine the safety and feasibility of the transendocardial injections of ADRCs in no-option patients with ischemic cardiomyopathy. METHODS AND RESULTS: Procedural, postoperative, and follow-up safety end points were monitored up to 36 months. After baseline measurements, efficacy was assessed by echocardiography and single-photon emission computed tomography (6, 12, and 18 months), metabolic equivalents and maximal oxygen consumption (MVO2) (6 and 18 months), and cardiac magnetic resonance imaging (6 months). We enrolled 21 ADRC-treated and 6 control patients. Liposuction was well tolerated, ADRCs were successfully prepared, and transendocardial injections were feasible in all patients. No malignant arrhythmias were seen. Adverse events were similar between groups. Metabolic equivalents and MVO2 values were preserved over time in ADRC-treated patients but declined significantly in the control group. The difference in the change in MVO2 from baseline to 6 and 18 months was significantly better in ADRC-treated patients compared with controls. The ADRC-treated patients showed significant improvements in total left ventricular mass by magnetic resonance imaging and wall motion score index. Single-photon emission computed tomography results suggested a reduction in inducible ischemia in ADRC-treated patients up to 18 months. CONCLUSION: Isolation and transendocardial injection of autologous ADRCs in no-option patients were safe and feasible. Our results suggest that ADRCs may preserve ventricular function, myocardial perfusion, and exercise capacity in these patients.